- Only 11% of patients required BPH drugs at 5 years post treatment
- 90% freedom from secondary procedures though 5 years
MINNEAPOLIS, April 26, 2011 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the manufacturer and marketer of minimally invasive Cooled ThermoTherapyTM (CTT), the durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today announced publication of long-term data in the May issue of The Journal of Urology. The study was conducted at leading urology centers in the US including: The Mayo Clinic, Johns Hopkins University Hospital, University of Texas Southwestern Medical Center, Duke University Medical Center and Virginia Urology Center. The study tracked 96% of patients through the duration of the study. The study is available through the following link:
The study demonstrates that Cooled ThermoTherapy is safe and effective at treating both symptoms and obstruction associated with BPH with results well maintained through 5 years. Dr. Claus Roehrborn, study investigator from the University of Texas Southwestern Medical Center remarked, "Durability is the name of the game. The better the results hold up over time, the fewer retreatments and the greater the benefit to cost ratio. In this context, the 5 year data from the Urologix Cooled ThermoTherapy Catheter (CTC) study are very reassuring." The men in the study group averaged 67 years of age and had an average prostate size of 50 grams, typical of many men taking one or even two chronic medications for their BPH. Only 11% of the men in the study went on BPH medication at any time during the 5 years of the study after Cooled ThermoTherapy.
"For the large population of men on BPH drugs that are bothered by inadequate symptom control, side effects, burdensome costs or risk of disease progression, this study confirms that Cooled ThermoTherapy is an effective and durable treatment option to consider that can provide freedom from their BPH pillbox," said Stryker Warren Jr., CEO of Urologix.
Cooled ThermoTherapy is recommended by the American Urological Association as a treatment option for patients with mild to moderate BPH. Urologix has treated more than 250,000 patients with Cooled ThermoTherapy, the leading office-based therapy for the treatment of BPH.
Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix' products include the CoolWave® and Targis® control units and the CTC Advance®, Targis® and Prostaprobe® catheter families. All of Urologix' products utilize Cooled ThermoTherapy™ - targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.
The Urologix, Inc. logo is available at
CONTACT: Brian J. Smrdel, Chief Financial Officer (763) 475-7696